51 completed, 17 terminated, 14 active not recruiting, 8 recruiting. 101 Phase 3, 14 Phase 2.
Follow Gemzar: new trials by email Literature Review of Gemzar trials Research Report on Gemzar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel - Carcinoma, Non-Small -Cell Lung | Phase 3 | Recruiting | Maia Biotechnology | 300 | 2025-12-08 | 2026-01-12 |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication - Triple Negative Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1000 | 2025-03-16 | 2026-11-10 |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) Pembrolizumab, Cisplatin, Carboplatin - Carcinoma, Non-Small-Cell Lung | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 680 | 2024-10-21 | 2026-11-09 |
| FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer FDA018-ADC, Eribulin, Capecitabine - Triple Negative Breast Cancer | Phase 3 | Active not recruiting | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 350 | 2024-08-09 | 2026-01-22 |
| A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Odronextamab, Ifosfamide, Carboplatin - B-Cell Non-Hodgkin Lymphoma (B-NHL) | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 216 | 2024-02-15 | 2026-05-11 |
| Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer Organoid-guided personalized treatment, Gemcitabine, Capecitabine - Breast Cancer, Refractory Breast Carcinoma | Phase 3 | Recruiting | Sun Yat-sen University | 302 | 2024-01-15 | 2024-02-20 |
| Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 disitamab vedotin, pembrolizumab, gemcitabine - Urothelial Carcinoma | Phase 3 | Active not recruiting | Seagen, a wholly owned subsidiary of Pfizer | 412 | 2023-09-22 | 2026-07-22 |
| Intravesical BCG vs GEMDOCE in NMIBC Gemcitabine, Docetaxel, Bacillus Calmette Guerin - Non-muscle-invasive Bladder Cancer | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 870 | 2023-02-07 | 2026-09-15 |
| Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed - NSCLC | Phase 3 | Terminated | EQRx International, Inc. | 8 | 2022-12-14 | 2024-05-02 |
| Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer SBP-101, Nab-paclitaxel, Gemcitabine - Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Panbela Therapeutics, Inc. | 600 | 2022-08-08 | 2024-11-06 |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel - Triple Negative Breast Cancer, PD-L1 Positive | Phase 3 | Active not recruiting | Gilead Sciences | 443 | 2022-07-25 | 2025-09-18 |
| Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin - Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Terminated | Mural Oncology, Inc | 456 | 2022-01-10 | 2025-08-28 |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer Biopsy Procedure, Biospecimen Collection, Cisplatin - Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 131 | 2021-11-12 | 2026-11-12 |
| Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR+FU/FA - Malignant Tumor of Pancreas Metastatic to Liver | Phase 2 / Phase 3 | Withdrawn | Sorrento Therapeutics, Inc. | 2021-11-01 | 2022-04-01 | |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 131 | 2021-06-28 | 2026-11-12 |
| Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) Pembrolizumab, Enfortumab vedotin (EV), RC + PLND - Bladder Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 808 | 2021-04-21 | 2026-07-16 |
| Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. Nab paclitaxel, Gemcitabine, mFOLFIRINOX - Pancreatic Adenocarcinoma | Phase 3 | Unknown | Fudan University | 600 | 2021-04-01 | 2021-04-08 |
| Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer Cisplatin, Gemcitabine Hydrochloride, Lymphadenectomy - Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8 | Phase 2 / Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 186 | 2021-02-24 | 2026-10-19 |
| Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) Gemcitabine, Cisplatin, Carboplatin - Bladder Cancer, Bladder Urothelial Carcinoma | Phase 3 | Recruiting | University Health Network, Toronto | 14 | 2021-02-08 | 2026-10-06 |
Showing 20 of 101. Sign in to see all of them.
Pancreatic Neoplasms (23) · Carcinoma, Non-Small-Cell Lung (17) · Breast Neoplasms (12) · Neoplasms (11) · Gallbladder Neoplasms (7) · Urinary Bladder Neoplasms (6) · Adenocarcinoma (5) · Cholangiocarcinoma (5) · Lung Neoplasms (5) · Neoplasm Metastasis (5) · Ovarian Neoplasms (5) · Parkinson Disease 4, Autosomal Dominant Lewy Body (5) · Triple Negative Breast Neoplasms (5) · Fallopian Tube Neoplasms (4) · Bile Duct Neoplasms (3)
National Cancer Institute (NCI) (10) · Eli Lilly and Company (9) · Merck Sharp & Dohme LLC (5) · Hellenic Oncology Research Group (4) · AB Science (3) · Celgene (3) · ECOG-ACRIN Cancer Research Group (3) · Gilead Sciences (3) · Fudan University (2) · Gynecologic Oncology Group (2) · NewLink Genetics Corporation (2) · Pfizer (2) · Spanish Lung Cancer Group (2) · Albert Koong (1) · Bristol-Myers Squibb (1)
United States (57) · Spain (33) · France (30) · Italy (29) · Belgium (28) · Canada (26) · Germany (26) · United Kingdom (26) · South Korea (24) · Australia (23) · Taiwan (23) · Austria (17) · Hungary (17) · China (16) · Greece (15)
Dimitris Mavrudis, MD (2) · Albert Koong (1) · Alessandra Curioni-Fontecedro, MD (1) · Antonio Jimeno, MD, PhD (1) · Ask Aabenhus, MSc. (Pharm) (1) · Athanasios Karampeazis, MD (1) · Bradley Monk (1) · Caicun Zhou, MD & PhD (1)
PMID 37185961, PMID 42176183, PMID 17329192, PMID 19560257, PMID 20164695, PMID 20375404, PMID 21444871, PMID 21783417, PMID 22124104, PMID 22162229, PMID 22266043, PMID 22285168, PMID 23229886, PMID 23537313, PMID 23642329, PMID 23690416, PMID 23940225, PMID 24131140, PMID 24493829, PMID 24906700, PMID 25082564, PMID 25164908, PMID 25398812, PMID 25492104, PMID 25498218, PMID 25638248, PMID 25713428, PMID 25806291, PMID 25858497, PMID 26091808, PMID 26141208, PMID 26181014, PMID 26372701, PMID 26489442, PMID 26655559, PMID 26802153, PMID 26802160, PMID 26945010, PMID 27259714, PMID 27264267, PMID 28438473, PMID 28636851, PMID 29129443, PMID 30472259, PMID 31253621, PMID 31722153, PMID 31849532, PMID 32374623, PMID 33070624, PMID 33093337
2023 (5), U10CA180820 (5), U10CA180868 (5), U10CA027469 (4), 2016 (2), 2019 (2), U10CA021115 (2), U10CA021661 (2), U10CA031946 (2), U10CA180821 (2), U10CA180888 (2), 2005 (1), 2017 (1), 2018 (1), N02CM62212 (1)